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Clinic at the Evangelic School of Medicine of Parana 11 months
ago with a history of edema and weakness. She was a retired
teacher and had been undergoing peritoneal dialysis for four
years. The cause of her chronic renal failure was polycystic
kidney disease, and she had started dialysis with a creatinine
clearance of 10 mL/min. In the beginning of the therapy, she
used a 2-liter exchange three times daily. The patient had felt
well during the first year of treatment and showed no signs of
underdialysis. She was 1.58 m tall and her weight was 67 kg
(body mass index, 26.8) when she started dialysis. She had
normal blood pressure, no edema, and her appetite was good.
The same pattern was present after one year of treatment.
Laboratory examination showed: hematocrit, 30%; albumin,
4.0 g/dL; urea, 128 mg/dL; and creatinine, 11.2 mg/dL. She had
been seen in the clinic two years earlier with her first episode
of exit-site infection. In the following month, she presentedCASE PRESENTATIONS
with a Staphylococcus aureus peritonitis, which was treated
Patient 1. A 50-year-old woman had chronic renal failure with a first-generation cephalosporin and an aminoglycoside.
secondary to long-standing arterial hypertension. When she Another episode of peritonitis occurred three months later and
started hemodialysis thrice weekly 10 years ago, she had a “dry was characterized as a recurrent infection. The same bacteria
weight” of 49 kg; height, 1.54 m; body mass index, 20.7; and grew in an exit-site smear culture. The infection was treated
serum albumin, 3.1 g/dL. She had been anorectic and asthenic, with a new course of the same antibiotic regimen. A tunnel
and peripheral edema was present. Eight years ago, her dry infection was diagnosed two months later and the catheter was
weight was 51.5 kg; body mass index, 21.7; and serum albumin, replaced. Two months after the tunnel infection, she weighed
3.1 g/dL. Despite good appetite, dietary evaluation revealed 66 kg, her albumin was 3.2 g/dL, and the serum urea was
that she was taking 22 kcal/kg/day and her normalized protein 108 mg/dL. Her appetite decreased throughout the following
catabolic rate was 0.68 g/kg/day. Her urea reduction ratio months, despite an uneventful dialysis treatment. The albumin
(URR) was 61.2%. Six years ago, her dry weight was 52 kg; level did not increase, and she lost 2 kg during the calendar
body mass index, 21.9; and serum albumin, 3.1 g/dL. Ten year. Two years ago, the dialysis prescription was changed to
months later, nutritional oral supplementation was initiated. 8 liters per day, with one hypertonic exchange at night. Four
Her dry weight had dropped to 48 kg, and the body mass index months later, she had another episode of Staphylococcus aureus
was 21.1. It became apparent to the social worker and dietitian peritonitis. Despite the increased dialysis dose, she developed
that she could not afford to purchase her basic nutrients and hypertension and had problems keeping her dry weight. Edema
that she had difficulty chewing the food because of poor teeth. was noticeable at most of her clinic appointments. A standard
Ten months ago, her dry weight had reached 56 kg; body peritoneum equilibrium test showed a high transport pattern,
mass index, 24.5; and serum albumin, 4.0 g/dL. Her normalized with a 4-hour dialysate/plasma ratio of creatinine of 0.81. Anal-
protein catabolic rate was 0.82 g/kg/day; URR, 72.8%; and ysis of the adequacy of dialysis showed a total corrected creati-
Kt/Vurea, 1.56. She is still receiving oral nutritional supplementa- nine clearance of 42 liters/week and a Kt/V of 1.74. At that
tion and doing well after almost 10 years on dialysis. time her normalized protein catabolic rate was 1.2 g/kg/day.
Patient 2. A 51-year-old woman presented to the Renal The albumin level 11 months ago was 2.9 g/dL and her weight
was 63.8 kg (estimated dry weight, 62 kg; body mass index,
24.8) and edema was still present. She was admitted to the
The Nephrology Forum is funded in part by grants from Amgen Incor- hospital for control of her edema and hypertension, and she was
porated; Merck & Co., Incorporated; AstraZenca LP; Dialysis Clinic, switched to daytime chronic ambulatory peritoneal dialysis.
Incorporated; and R & D Laboratories.
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Table 1. Nutritional evaluation in dialysis patientsgelic School of Medicine of Parana, Curitiba, Parana,
Brazil): These two patients illustrate the spectrum of Clinical
Medical historymalnutrition in our current dialysis population. At one
Physical examinationend of the spectrum is malnutrition due to poor nutrient Nutrient physical examination (NPE)
intake (malnourishment); at the other end of the spec- SGA: subjective global assessment
Nutritional intaketrum is malnutrition due to a reduction in somatic and
Dietary history and dietary recordsvisceral proteins as a result of a hypercatabolic state (an Appetite assessment: Appetite and Diet Assessment tool (ADAT)
inflammatory response). In this Forum, I will examine Urea appearance (estimation of protein intake)
Biochemicalboth sides of this spectrum.
Visceral protein stores: plasma proteins (albumin, prealbumin, trans-Malnutrition has been reported to vary from 10% to ferrin, IGF-1)
70% in hemodialysis patients and from 18% to 51% Static protein reserves: serum creatinine, urinary creatinine output,
creatinine-height index, 3-methylhistidinein continuous ambulatory peritoneal dialysis (CAPD)
Other plasma and blood chemistries (hemoglobin, urea, creatinine,patients [1]. The signs of malnutrition are reduced subcu- lipids, amino acids)
taneous fat stores (reduced energy stores) and decreased Biochemical analysis of skeletal muscle: alkali-soluble protein, DNA,
RNA, amino acidsmuscle mass (as assessed by anthropometric methods),
Vitamins, minerals, and trace elementslow total-body nitrogen determined by in vivo neutron Fluid, electrolyte, and acid-base status
activation analysis [2], hypoalbuminemia, low transferrin Body weight
Actual, compared to standards and weight changeand other visceral proteins, low alkaline-soluble protein
BMI (body mass index)in muscle in relation to dry fat-free weight and DNA Body composition
[3], and abnormal plasma amino acids and intracellular Direct methods
Neutron activation analysisamino acid profiles [4]. However, some hemodialysis pa-
Computed tomographytients have a normal nutritional status [5]. The anthropo- Magnetic resonance imaging
metric data indicate that energy malnutrition is more Dual energy X-ray absorptiometry (DEXA)
Total body waterprevalent than is protein malnutrition in hemodialysis
Indirect methodspatients, but these anthropometric methods may under- Hydrodensitometry
estimate protein depletion [6]. In one study, total-body Bioelectric impedance
Anthropometry: skinfold thickness, midarm muscle circumferencenitrogen determined by neutron activation analysis was
Immunologic methodsmore sensitive in detecting protein depletion than were Total lymphocyte count
anthropometric measurements [7]. Delayed hypersensitivity skin tests
The anthropometric measurement of body mass index
(BMI), calculated as an individual’s weight in kilograms
divided by the square of the individual’s height in meters
(kg/m2), correlates with measures of body fat and is used
disease, iron-deficiency anemia, and chronic inflamma-as a marker of energy nutritional status (energy stores).
tion [10]. More sophisticated methods of body composi-Comparisons of BMI among female and male hemodial-
tion analysis, such as neutron activation analysis, can beysis patients and the general U.S. population reveal that
used to quantify body cell mass and other body compart-in all age groups and both genders, mean BMI is signifi-
ments but are costly and not widely available [7].cantly lower in hemodialysis patients than in the respec-
Ideal nutritional assessment should be able to detecttive general population samples [8]. Young et al exam-
the entire range of poor nutrition, from subclinical mal-ined the nutritional status of 224 CAPD patients from
nutrition to overt malnutrition, assess macro- and micro-six centers in Europe and North America and assessed
nutrient deficiencies, and grade the overall nutritionalthe incidence of protein-energy malnutrition. Using a
status of the patient. Since no single measurement cansubjective nutritional assessment, the authors found that
accomplish all of these goals [11], many indices, each8% of the patients were severely malnourished, 33%
representing a specific data category, are measured inde-were mildly to moderately malnourished, and 59%
pendently and then evaluated collectively to ascertainshowed no evidence of malnutrition [9].
the nutritional status of the patient (Table 1).
Evaluating nutritional status in dialysis patients A good method for estimating the protein intake quan-
titatively is a determination of the “total nitrogen appear-The ideal protocol for diagnosing malnutrition in pa-
ance” (TNA), which is defined as the sum of all nitrogentients with renal disease has not been created. Many
losses from the body plus the change in body nonproteinbiochemical indicators of nutrition—such as serum albu-
nitrogen (mainly urea nitrogen). Total nitrogen appear-min, creatinine, transferrin, and cholesterol—are useful
ance reflects the net breakdown of protein which, in thein identifying high-risk groups but often are abnormal
steady state, is equal to the intake of nitrogen, the mainonly late in the course of a deteriorating nutritional state.
Moreover, they can be confounded by concomitant liver source of which is ingested protein [11].
Nephrology Forum: Malnutrition in dialysis 1213
By measuring the urea losses in the urine and dialysate at least one-half the protein ingested should be of high
biologic value.as well as the changes in blood urea nitrogen in CAPD
Low caloric energy intake appears to be more commonpatients, one can calculate the urea nitrogen appearance
and severe than is decreased protein intake in most pa-(UNA), which closely reflects TNA. In hemodialysis pa-
tients on maintenance hemodialysis [13]. The low energytients, one needs to measure urea concentrations before
intake does not reflect a decrease in energy require-and after dialysis, dialyzer clearance, and dialysis time.
ments. Indirect calorimetry studies have shown that en-The protein equivalent of nitrogen appearance, PNA
ergy expenditure in maintenance hemodialysis patients(formerly protein catabolic rate), has been found to be
appears similar to that of normal individuals [14]. But a6.25 times TNA, which in the steady state reflects protein
more recent study, using whole-room indirect calorime-intake [11]. For CAPD patients, the Bergstro¨m et al I
try, reported that resting energy expenditure (REE) isand II formulas are recommended [11]. Equation 1 might
actually higher in maintenance hemodialysis patients,be simpler to use, as it does not require direct analysis
even on non-dialysis days, compared to age-, gender-,of protein losses, but it can yield less-accurate values
and body-mass-index-matched normal controls [15]. Thiswhen the protein losses are high. In Equation 2, the
higher REE in hemodialysis patients was calculated toprotein losses in dialysate and urine should be added.
be 8% to 16% greater than that in normal individuals.
PNA (g/24 h) 5 20.1 1 7.50 UNA (g/24 h) Most studies in patients on maintenance hemodialysis
(Eq. 1) indicate that energy intake frequently is below the rec-
ommended level for normal healthy adults, usually aver-PNPNA (g/24 h) 5 15.1 1 6.95 UNA (g/24 h)
aging approximately 24 to 27 kcal/kg/day [13]. In the(Eq. 2)
Hemo Clinical Trial, in which patients are seen periodi-
where PNPNA represents protein equivalent of nonpro- cally by renal dietitians, the energy intake averaged 22.8 6
tein nitrogen appearance which, in the steady state, ap- 8.8 (mean 6 SD) kcal/kg adjusted body weight/day [13].
proximates the net protein intake, that is, total protein The findings of low body fat and decreased skinfold
intake minus total protein losses. thickness in maintenance hemodialysis patients [16]
What are an individual’s protein and energy require- seem to support the thesis that the usual energy intake
ments? The protein requirement is defined as the lowest of these individuals is inadequate. Slomowitz et al carried
level of dietary protein intake that will balance the losses out metabolic balance studies in six maintenance hemo-
of nitrogen from the body in a person who maintains dialysis patients who lived in a clinical research center
energy balance at modest levels of physical activity. Most for 63 to 65 days and who underwent hemodialysis for
estimates of human protein requirements have been ob- four hours three times per week with Cuprophan or
tained from measurements of nitrogen balance. The cellulose acetate dialyzers [17]. These patients were fed
mean value obtained for adults has been 0.6 g/kg/day a constant-protein diet that provided 1.13 6 0.02 (mean 6
with a coefficient of variability of 12.5% [12]. Hence, a SEM) g/kg/day, but were fed three different dietary en-
value of 25% (2 SD) above the mean physiologic require- ergy intakes (in a random fashion) for 21 to 23 days
ment for the adult would meet the needs of all but 2.5% each that provided 25, 35, and 45 kcal/kg/day. Nitrogen
of people in the adult population. Thus, the mean re- balance was negative, neutral, and positive for the diets
quirement should be increased to 0.75 g/kg/day to pro- providing 25, 35, and 45 kcal/kg/day, respectively [17].
vide a safe protein intake for healthy adults. Some adults Nutritional surveys indicate that mean protein intake is
may require as little as 0.45 g/kg/day of high-quality less than 1 g/kg/day in a large proportion of patients
protein [12]. on maintenance hemodialysis [3, 18]. However, many
Surprisingly few studies have assessed the dietary pro- investigators have shown that chronic renal failure and
tein requirements for patients on maintenance hemodial- ESRD patients can maintain nitrogen balance despite
ysis [13]. Most of the studies addressing protein require- significantly lower protein intake [19]. Based on the
ments in hemodialysis patients were carried out several available evidence, I believe it appropriate to recom-
years ago and used dialyzers and dialyzer clearances that mend an energy intake of 35 kcal/kg/day for clinically
are no longer in use. Given the fact that (1) there is a stable patients on maintenance hemodialysis. Patients
high prevalence of protein malnutrition in maintenance older than 60 years might need only 30 kcal/kg/day [13].
hemodialysis patients, (2) metabolic studies clearly indi-
Causes of dialysis malnutritioncate that 0.75 g protein/kg/day is nutritionally adequate
for many hemodialysis patients [13], and (3) 1.1 g protein/ The multifactorial reasons for malnutrition in dialysis
kg/day will maintain nitrogen balance in some but not patients include disturbances in protein and energy me-
all patients who are ingesting 25 or 35 kcal/kg/day, a tabolism, hormonal derangement, poor intake due to
dietary protein intake of 1.2 g/kg/day is recommended anorexia, and nausea and vomiting related to the uremic
toxicity. Many underlying diseases such as diabetes melli-[13]. To ensure adequate intake of essential amino acids,
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Table 2. Causes of anorexia in maintenance dialysis patients uremia depends to some extent on the accumulation of
uremic toxin (possibly a middle molecule). Studies bothDietary restriction (limited choice and palatability)
Frequent hospitalizations and surgical procedures in maintenance hemodialysis patients and chronic perito-
Psychosocial and economic factors: depression, loneliness, ignorance, neal dialysis patients indicate that as the dialysis dosepoverty, poor dental status, alcohol and drug abuse
(indicated by Kt/V) increases, dietary protein intake in-Inadequate dialysis (uremic toxicity)
Inflammation, infection, sepsis creases [22]. Other data, however, show no relation be-
Underlying diseases tween these variables in patients who are “adequately”Gastropathy (diabetics)
dialyzed [24], defined as having a Kt/V of $0.9. Berg-Medications
? Hyperleptinemia stro¨m and Lindholm illustrated the correlation between
? Cytokines Kt/Vurea and the estimated protein intake in a group ofEffects of hemodialysis: cardiovascular instability, nausea and vom-
151 hemodialysis patients in whom the Kt/V was belowiting, postdialysis fatigue
Effects of peritoneal dialysis: abdominal discomfort, absorption of 1.0 [1]. This group, reinvestigated two years later when
glucose and amino acids, peritonitis the Kt/V was desirable, no longer showed this correla-
tion. It appears that in well-dialyzed patients, the level
of protein intake is independent of the dialysis dose [6]. If
the patient has a very low Kt/V—to a point of producing
uremic symptoms—increasing the dialysis dose shouldtus, diffuse vascular disease (coined vascular cachexia),
improve appetite and food intake. The question remainsand superimposed illness (pericarditis, infection, conges-
whether an increase in Kt/V above the previously accept-tive heart failure) also can contribute to malnutrition.
able levels will further increase protein and energy in-Let us analyze first one end of the malnutrition spectrum:
take. No study has examined whether such an increasepoor nutrient intake. The main reason for inadequate
in the dialysis dose will enhance dietary energy intake.nutritional intake is a decrease in appetite (anorexia)
The relationship between Kt/Vurea and protein intakethat can have many causes (Table 2).
might simply reflect a mathematical coupling becauseAlthough many of the causes of anorexia in dialysis
both variables share several components: both are nor-patients are acceptable and understandable, some are
malized to body size and both depend on urea in plasmapoorly understood, particularly the anorexia related to
before and after dialysis. However, some data show a
uremic toxicity. A reasonable hypothesis is that inhibi-
relationship between the quantity of urea removed and
tion of appetite is caused by retention of toxic substances protein intake that is calculated from the dietary records
as a consequence of reduced renal function. Low-protein and interviews. In CAPD patients, this relationship could
diets ameliorate the uremic symptoms of anorexia, nau- be demonstrated even when the quantity of urea or creat-
sea, and vomiting. This finding suggests that some of inine removed was not normalized to body size [21].
these toxins are generated by dietary protein breakdown. Hakim et al reported a prospective study in which the
Recent studies indicate that many patients decrease di- dialysis dose was increased progressively in 130 hemodi-
etary protein intake with the progression of renal failure; alysis patients. During a four-year period, the dialysis
protein intake can fall as low as 0.6 g/kg/day when creati- dose (measured by delivered Kt/V) was gradually in-
nine clearance is less than 10 mL/min [20]. The observa- creased to 1.33. They found a strong positive correlation
tion that anorexia, nausea, and vomiting diminish or between the dialysis dose and protein intake. Moreover,
disappear at the start of dialysis suggests that a readily nutritional indicators (serum albumin, transferrin, PCR)
dialyzable substance is removed through conventional differed significantly between the groups with an average
cellulosic dialysis membranes. Assuming that a dialyz- Kt/V below 0.86 and above 1.21 [25], higher values being
able uremic toxin accumulates in severe renal failure and found in the group with the latter Kt/V. However, Lowrie
causes anorexia, it is understandable that underdialysis reported no significant correlation between the dose of
can affect the appetite and thus cause poor nutrient in- hemodialysis, estimated as the urea reduction rate, and
take. the serum albumin concentration [26]. In another study,
Several studies in dialysis patients report a significant hypoalbuminemic patients on hemodialysis were moni-
correlation between dose of dialysis for small-molecule tored longitudinally while receiving a Kt/V of 1.3. In
removal (Kt/Vurea) and the protein intake, especially in these patients, the serum albumin increased significantly
the lowest dose intervals [21, 22]. Nearly two decades [27]. Although Owen et al failed to show a correlation
ago, the National Cooperative Dialysis Study (NCDS) between serum albumin levels and increasing dialysis
showed a correlation between protein intake and length dose in hemodialysis patients, the mortality rate im-
of dialysis. The two groups on dialysis of shorter duration proved with an increasing urea reduction rate [28]. Thus,
had lower mean protein intakes at the end of six months it remains controversial whether the dialysis dose has
than did the two groups whose dialysis time was longer an impact on nutrition and whether the correction of
underdialysis improves the patient’s nutritional status.[23]. These results suggest that appetite suppression in
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My own practice is to guarantee “adequate dialysis” reduce the synthesis and release of neuropeptide Y, one
through a Kt/Vurea of 1.3 or eKt/Vurea of 1.2. In patients of the most potent appetite stimulants yet demonstrated
with low nutritional indices and “adequate dialysis” for [33]. Thus, leptin is presumed to be a powerful regulator
at least six months, lack of improvement suggests alter- of the brain’s satiety center [33].
nate factors in the genesis of these low nutritional indices. Clinical studies have shown that obese patients have
I don’t believe that going beyond what now is considered high circulating levels of leptin, suggesting resistance to
“adequate dialysis” will improve these indices. the action of leptin [32]. This is a similar situation to the
db/db mouse, which has a mutation in the leptin receptor
How does residual renal function affect nutrition? gene and manifests hyperleptinemia due to leptin resis-
Using multiple regression analysis, Bergstro¨m et al tance [34]. Many patients with end-stage renal disease
showed that the renal component of the total clearance (ESRD) are hyperleptinemic due to impaired renal clear-
of urea or creatinine correlated significantly with dietary ance and/or increased synthesis. Because of the high prev-
protein intake in CAPD patients, whereas the dialytic alence of malnutrition and reduced food intake in ESRD
clearance showed no such relationship. This finding sug- patients, understanding the regulation of leptin in uremia
gests that in CAPD patients, residual renal function has would be valuable. Previous studies have shown that
a greater influence than does the dose of peritoneal dial- insulin stimulates expression of the ob gene and increases
ysis on the appetite for protein [21]. Some longitudinal plasma leptin levels; thus, hyperinsulinemia due to insu-
studies show that total-body nitrogen decreases during lin resistance in uremia is expected to result in hyperlep-
the first two years of CAPD treatment concomitantly tinemia [35].
with a decrease in protein and energy intake, and that In normal individuals, the estimated net renal extrac-
protein intake decreases along with the loss of residual tion of circulating leptin is approximately 12%; it is virtu-
renal function [29]. An international cross-sectional multi- ally 0% in patients with renal failure [36]. Leptin levels in
center study revealed that lack of residual renal function CAPD patients appear to be higher than in hemodialysis
is associated with anorexia and symptoms of malnutri- patients because of less-efficient clearance or greater
tion [9]. These findings support the hypothesis that some synthesis [37]. The pathophysiologic significance of in-
compounds normally excreted in the urine (even in pa- creased circulating levels of leptin in ESRD patients is
tients with severe renal failure) are retained in the not clear. If leptin receptors are not down-regulated,
plasma of CAPD patients and cause anorexia. chronic serum leptin elevation could affect appetite and
As I mentioned earlier, the improvement in appetite nutritional status. Nishizawa et al measured plasma lep-
that occurs after initiation of dialysis substantiates the tin levels in 103 patients on hemodialysis and found levels
possibility that one or more uremic toxins cause an-
significantly higher than those in controls: 13.9 6 2.1 ng/
orexia. The report that protein intake increases propor-
mL versus 7.6 6 0.5 ng/mL (P , 0.0001) [38]. Womentionally more with a given increase in Kt/Vurea with a high- had higher levels in both groups, and leptin levels corre-flux membrane than a low-flux membrane suggests that
lated with percentage of body fat, being higher in patientsa middle-molecule compound causes anorexia [22]. Berg-
with 30% or more of body fat. Leptin levels did notstro¨m’s group has isolated and characterized factors in
correlate with lean body mass (Fig. 1). If impaired leptinuremic plasma that suppress appetite. Injecting ultrafil-
clearance alone could explain the hyperleptinemia, ittrate from uremic plasma of patients with end-stage renal
would not explain the observation that leptin is elevatedfailure into the peritoneum of rats inhibited the ingestion
only in obese patients on hemodialysis. Heimbu¨rger andof both carbohydrate (sucrose) and protein; injection of
colleagues also demonstrated a good correlation be-normal plasma had no effect [30]. The authors isolated
tween serum leptin levels and body fat and suggesteda fraction in the molecular weight range of 1 to 5 kD
that leptin could be a marker of body fat content inthat suppressed appetite in rats in a dose-dependent way.
patients with chronic renal failure [39]. At present theThe obesity (ob or lep) gene has been cloned [31] and
significance of uremic hyperleptinemia is unknown. Ifits protein product leptin (Greek leptos, thin) has been
future studies reveal the need to reduce leptin levels (oridentified. The lep gene is expressed exclusively in fat
reduce the resistance to leptin) in ESRD patients, thencells that synthesize and secrete leptin into the circula-
control of body weight, use of high-flux dialyzers, andtion. Administration of recombinant leptin elicits im-
renal transplantation might be indicated [32].pressive biologic effects in mice: inhibition of food in-
Yet another group of compounds has been suggestedtake, stimulation of energy expenditure, reversal of
as contributing to anorexia in dialysis patients. Severalobesity, amelioration of insulin resistance, and accelera-
cytokines have been reported to suppress appetite andtion of sexual maturation [32]. Leptin’s site of action is
thus might contribute to malnutrition [40]. However,thought to be the hypothalamic appetite center, although
Kaizue et al did not find a difference in PCR, an indicatorleptin receptors have been reported in pancreas, liver,
and kidney [32]. In the hypothalamus, leptin appears to of dietary protein intake under stable conditions, be-
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Fig. 1. Comparison of plasma leptin levels
between hemodialysis patients (h) and con-
trol subjects (j) in the same range of percent-
age body fat. *P 5 0.016 and **P 5 0.005 by
Student’s t-test. (Used with permission from
Am J Kidney Dis [38].)
Table 3. Protein catabolic factors in dialysis patientsatween patients with a high serum IL-6 level and those




Because dialysis patients have increased protein re- Endocrine abnormalities
Corticosteroid therapyquirements and reduced utilization of ingested protein
Inflammation, infection, sepsiscompared to normal subjects, metabolic factors might Acidosis
stimulate net protein catabolism and impair utilization Amino acid abnormalities
Factors related to hemodialysisof ingested protein [42]. The literature contains ample
Loss of amino acids, 9–13 g/sessionevidence of marked protein catabolism in uremic rat Loss of glucose, 25 g/session (glucose-free dialysate)
models [43]. Dialysis, with its obligatory protein and Loss of protein (minor)
Inflammatory stimuli: blood-dialyzer contactamino acid losses, is inherently a catabolic stress [44].
Complement activationFurthermore, during hemodialysis, protein degradation Endotoxins
can be increased by bioincompatible membranes (Table Cytokines
Acetate3). Using 13C-leucine kinetics, Berkelhammer et al stud-
Factors related to CAPDied a group of well-nourished adult hemodialysis patients Loss of amino acids, 2–4 g/day
whose diet contained 1.0 g/kg/day of protein and 30 to Loss of protein, 5–15 g/day
Inflammatory stimuli: ? particles, chemicals40 kcal/kg/day. Fasting rates of whole-body protein syn-
Peritonitisthesis and breakdown were normal, whereas rates of Cytokine release
amino acid oxidation (that is, net proteolysis) were in-
a Based on work by Bergstro¨m J [6]
creased [45]. However, the metabolic acidosis (serum
bicarbonate, 18 6 1 mEq/L) in this study might have
been responsible for the increased oxidation rate. In
kinetic leucine studies performed three months after ini- and dialysate losses of amino acids. The increased pro-
tiation of CAPD, protein turnover and the rate of protein tein catabolism observed during dialysis was attributed
oxidation were lower than in controls [46]. The low pro- to a suppression of whole-body protein synthesis and
tein intake in these patients might explain the low amino dialysate losses of amino acids [44].
acid oxidation rates. Lim et al measured fasting whole- In healthy subjects, nitrogen balance depends greatly
body protein turnover in seven patients before, during, on energy intake. High energy intake has a protein-
and after high-efficiency hemodialysis using Cuprophan sparing effect; low energy intake results in negative nitro-
dialyzers [44]. Whole-body protein synthesis and leucine gen balance [42]. Bergstro¨m et al performed nitrogen
oxidation both were decreased during hemodialysis; in balance studies in CAPD patients and verified that
contrast, protein degradation was unchanged. Net leu- within two to six months after the start of CAPD, dietary
cine balance (the difference between synthesis and deg- protein intake and total energy intake significantly corre-
radation) became more negative during dialysis; this lated with the nitrogen balance [21]. However, in later
studies (9 to 16 months on CAPD), protein intake hadchange was attributed to impairment in protein synthesis
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no influence on nitrogen utilization, and energy intake mildly acidotic patients on hemodialysis, protein degra-
dation and synthesis decreased but oxidation did not.seemed to have an even stronger influence [21]. The
findings indicate that energy deficiency is detrimental to The reduction in plasma urea that occurred after correc-
tion of the acidosis reflected the decrease in proteinthe utilization of dietary protein in CAPD patients [21].
Metabolic acidosis also has been identified as an im- degradation. The authors noted no change in body com-
position but the study period was only 10 weeks [55].portant stimulus of protein catabolism. Acidosis is the
only metabolic factor (“uremic toxin”) identified to date The clinical significance of metabolic acidosis as a fac-
tor for the development of malnutrition has not beenthat induces catabolism and impairs nitrogen utilization
in uremia [42]. Acidosis also induces insulin resistance, determined. Lowrie and Lew analyzed laboratory data
and mortality rates in more than 12,000 hemodialysisdemineralizes bones, decreases the sensitivity of PTH
to serum calcium concentration, and impairs growth in patients. The death risk was significantly increased in
patients with metabolic acidosis, but only in those inchildren [47].
Animal studies have demonstrated that chronic meta- whom the serum total CO2 levels were lower than 12.5
mmol/L [56]. No association was noted between totalbolic acidosis, rather than uremia per se, accelerates pro-
teolysis [48]. This effect seems to be mediated by the CO2 levels and nutritional factors, as assessed by serum
albumin and cholesterol levels. Bergstro¨m also foundstimulation of branched-chain keto-acid decarboxylation
in skeletal muscle, which increases the catabolism of the no correlation between standard bicarbonate and serum
albumin levels in 133 hemodialysis patients [42]. It isbranched-chain amino acids (valine, leucine, isoleucine)
[48]. Evidence indicates that acidosis stimulates proteol- conceivable that a high protein intake stimulates protein
synthesis to the extent that the negative effect of theysis in muscle by inducing the transcription of genes en-
coding for enzymes participating in the ATP-dependent increased activation of proteolysis characteristic of meta-
bolic acidosis is overcome [42]. Brady and Hasbargencytosolic ubiquitin-proteasome proteolytic pathway and
that cortisol is required for the activation to occur [48]. studied 36 hemodialysis patients whose mean serum bi-
carbonate concentration was less than 18 mEq/L beforeHuman studies have demonstrated amino acid abnor-
malities that correlate with the degree of metabolic aci- dialysis [57]. They kept one-half of the patients on a con-
ventional bicarbonate bath of 35 mEq/L but increased thedosis in hemodialysis patients [4] and also have shown
that metabolic acidosis impairs nitrogen utilization and bicarbonate bath concentration to 40 mEq/L in the other
half. After four months, no difference in serum albuminaccelerates the loss of lean body mass in patients with
chronic uremia [49]. Ammonium chloride-induced meta- and total lymphocyte count was apparent between the
groups [57]. The protein catabolic rate (PCR) was un-bolic acidosis in healthy humans decreases albumin syn-
thesis and induces negative nitrogen balance [50]. In changed in both groups during the study. However, the
serum albumin in the control group was 3.88 6 0.28 g/dLnon-dialyzed patients with chronic uremia, correction of
metabolic acidosis improves nitrogen balance and re- and 3.76 6 0.26 g/dL in the experimental group, and this
finding might explain a lack of improvement (low-normalduces urea appearance, muscle proteolysis [49], and leu-
cine oxidation [51]. Similarly, correction of metabolic serum albumin at start in both groups and not much
difference between groups). Movilli et al administeredacidosis in patients on peritoneal dialysis decreases
whole-body protein degradation [52]. Lim et al recently oral sodium bicarbonate (mean dose, 2.7 6 0.94 g/day;
range, 1 to 4 g/day) to 12 hemodialysis patients for threemeasured in vivo whole-body protein turnover in nine
patients with chronic renal failure before initiation of months, raising the serum bicarbonate from 19.3 6 0.6
mmol/L to 24.4 6 1.2 mmol/L (P , 0.0001) [58]. Serumdialysis and 8 to 10 weeks later [53]. Leucine flux was
measured when the patients were acidotic as well as after albumin increased from 3.49 6 0.21 g/dL to 3.79 6 0.29
g/dL (P , 0.01) during the study period. Of note is thecorrection with sodium bicarbonate. The authors found
that uremia per se was not a catabolic state, and protein fact that the normalized PCR (nPCR) decreased during
the period; the authors attributed the fall to a decreaseturnover was in fact down-regulated. The data indicated
that when acidosis was corrected, patients with chronic in catabolism of endogenous proteins [58]. Recent work
also describes increases in triceps skinfold thickness andrenal failure adapted to lower protein intake by reducing
amino acid oxidation and protein degradation, and main- body weight after correction of metabolic acidosis in he-
modialysis [59] and CAPD [60] patients. These findingstained protein synthesis at normal levels. Maintenance
dialysis treatment over time restored protein flux to nor- suggest an associated improvement in nutritional status.
In conclusion, we have significant evidence both frommal and increased protein synthesis [53].
Not all human data, however, are consistent with hyp- animal and human studies that metabolic acidosis in-
duces protein catabolism. However, the evidence thatercatabolism. Goodship and colleagues did not find in-
creased protein degradation or increased leucine oxida- correction of acidosis in dialysis patients improves nutri-
tional status comes from short-term studies that mighttion in six mildly acidotic predialysis patients [54]. When
Graham and coworkers corrected the acidosis of six have long-term implications: improvements in metabolic
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bone disease, proper growth, and the sense of well-being other factor contributing to the patient’s nutritional sta-
tus. The best evidence that blood-membrane contact in-felt by the dialysis patient. Bailey and Mitch have recom-
mended that we maintain the predialysis serum bicar- duces protein catabolism and that biocompatibility of
the membrane plays a role in nutrition comes from abonate as close to 24 mmol/L as possible through adjust-
ments of the dialysis bath or the utilization of sodium series of experiments with sham dialysis in normal indi-
viduals [65, 66]. Blood-membrane contact within a dia-bicarbonate supplements [47].
Dialysis alters glucose metabolism and thus affects lyzer with Cuprophan membrane elicited an increased
release of amino acids from the leg tissue that corre-nutrition. During a single dialysis session using conven-
tional glucose-free dialysate, glucose losses have been sponded to an increased protein breakdown of 15 to 20 g.
Dialysis with a more biocompatible membrane, AN 69S orestimated at 25 to 30 g [61]. To maintain glucose homeo-
stasis, these losses, together with those arising from nor- polysulfone, produced no increase in amino acid release.
Also, Cuprophan, but not the more biocompatible mem-mal body utilization, are replaced by mobilization of
liver glycogen stores and gluconeogenesis. In addition branes, was associated with an increased release of methyl-
histidine from the leg muscles and an elevation of theto the protein catabolism due to gluconeogenesis, further
protein breakdown replaces amino acid losses. Dialysis plasma methylhistidine concentration. This efflux of meth-
ylhistidine from the leg implies that increased proteintherapy therefore would be expected to promote protein
catabolism, as discussed earlier. This hypothesis is sup- breakdown plays an important part in the net catabolic
process induced by blood-membrane contact. Thus, theported by the observation of an increase in urea genera-
tion and a negative total nitrogen balance on the day hemodialysis procedure likely elicits an inflammatory
reaction depending on the membrane material used; thisof dialysis when a glucose-free dialysate is used [61].
Gutierrez et al verified that after an overnight fast, the response is more marked with cellulosic than with syn-
thetic membranes [42]. It appears that complement isefflux of amino acids in the dialysate did not differ during
hemodialysis, with or without glucose in the dialysis fluid activated with the release of anaphylatoxins (C3a, C5a);
and monocyte activation releases cytokines (IL-1, TNF,[62], and thus the addition of glucose had no protein-
sparing effect. and other cytokines) as a result of direct membrane con-
tact, activated C5a, endotoxin fragments passing throughAmino acid losses also occur during dialysis. The total
loss of amino acids is about 10 to 13 g per dialysis (5 to the membrane, and dialysate acetate [42]. Despite these
reports, Lim et al did not confirm increased catabolism8 g of free amino acids and 4 to 5 g of peptide-bound
amino acids). Ikizler et al examined amino acid and after dialysis with an unsubstituted cellulose membrane
[44]. Their study disclosed evidence of decreased anabo-protein losses in patients undergoing hemodialysis with
three types of dialyzer membranes [63]. The patients on lism during and after dialysis, which was attributed to
amino acid removal during dialysis. Lindsay and Spannerhigh-flux polysulfone membranes lost 8.0 6 2.8 g (mean 6
SD) of amino acid per dialysis session, as compared to showed in 1989 that the relationship between protein
catabolic rate and Kt/Vurea can be separated according topatients dialyzed with low-flux polymethylmethacrylate
membranes, who lost 6.1 6 1.5 g of amino acids (P , patients dialyzed by devices containing cellulose acetate
membranes and patients dialyzed by devices containing0.05), and those dialyzed with cellulose acetate mem-
branes, who lost 7.1 g 6 2.6 g (NS). Protein losses during the synthetic AN 69S membrane [22]. The slope of the
relationship for the former is significantly less than thehemodialysis typically are very small, but they can be
higher with high-flux (polysulfone) dialyzers and particu- slope for the latter. In a prospective study, they also
showed that after six months, there was an increase inlarly after reuse with bleach and formaldehyde. Ikizler
et al found that albumin losses became apparent after the slope when the patient’s dialysis was changed from
a cellulosic to an AN 69S membrane. These data indicatethe sixth reuse of the high-flux polysulfone membrane,
reached 1.5 6 1.3 g per session by the 15th reuse, and that patients using a more biocompatible membrane
(AN 69S) achieve the same protein catabolic rate for lesspeaked at 9.3 6 5.5 g at the 20th reuse [63]. Kaplan and
coworkers observed similar results [64]. The amino acid Kt/Vurea than do patients using cellulosic membranes [22].
losses increased by 50% after the 6th reuse in the high-
Uremic inflammatory responseflux polysulfone membranes. The loss of free amino acids
into the dialysate during CAPD is of the same magnitude What about malnutrition as an expression of uremic
inflammatory response? Kaysen et al measured albumin(per week) or smaller than in hemodialysis [13]. How-
ever, protein losses are higher in CAPD when compared synthesis, fractional catabolic rate, and the distribution
of albumin between the vascular and extravascular com-to hemodialysis and average 5 to 15 g per day. Variability
is wide among patients, and dialysate protein loss can partments from the turnover of [125I] human albumin in
six hemodialysis patients whose plasma albumin levelvary between 20 to 140 g per week. Peritonitis can in-
crease losses by 50% to 100%. was less than 3.5 g/dL and in six patients with a plasma
albumin level greater than 4.0 g/dL [67]. Both groupsBiocompatibility of the dialysis membrane is yet an-
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Fig. 2. Relationship between three-month
average serum albumin concentration and
C-reactive protein (CRP) concentration in he-
modialysis patients (left panel; r 5 0.490; P ,
0.001) and between three-month average al-
bumin concentration and CRP in peritoneal
dialysis patients (right panel, r 5 0.436; P ,
0.0016). (Reproduced with permission from
Kaysen G: Biological basis of hypoalbumi-
nemia in ESRD. J Am Soc Nephrol 9:2368–
2376, 1998.)
were maintained with high-flux polysulfone dialyzers for and apoA1. The positive APRs (C-reactive protein and
serum amyloid A being the most important) have a vari-longer than three months. The authors verified that albu-
min synthesis was significantly reduced in the low-albu- ety of actions that modulate the inflammatory response.
The significance of the downregulation of negative APRsmin group. Plasma albumin concentration also correlated
negatively with ferritin, C-reactive protein, and a2-macro- is not clear, but the liver might simply be shifting its
synthetic capacity away from negative APRs to concen-globulin. Plasma albumin concentration and albumin syn-
thesis rate were independent of PCR and other related trate on producing the positive APRs required for modu-
lation of inflammation [69]. C-reactive protein has longnutritional variables. Thus, hypoalbuminemia was due
to decreased albumin synthesis. To verify whether hypo- been used as a marker of inflammation. It is valuable in
monitoring inflammation in rheumatologic diseases asalbuminemia is a result of the acute-phase response,
Kaysen et al also measured serum albumin, C-reactive well as in a wide variety of inflammatory disorders such
as pancreatitis, myocardial infarction, pneumonia, osteo-protein, serum amyloid A, Kt/V, and nPCR in 115 hemo-
dialysis patients and found that most had normal C-reac- myelitis, and postoperative sepsis [69]. In more than 1000
randomly selected dialysis patients, Lowrie found an ele-tive protein and serum amyloid A levels and that a sig-
nificant minority had high levels [68]. A significant vated serum concentration of C-reactive protein in ap-
proximately 35% of the patients [70]. Although he wasnegative correlation existed between serum albumin and
both C-reactive protein and serum amyloid A (P , 0.001); able to correlate hypoalbuminemia with a high mortality
rate, Kaysen noted no such correlation with C-reactivethis correlation supports the hypothesis that a general-
ized acute-phase response lowers serum albumin (Fig. 2). protein [71]. On the other hand, it was found that ele-
vated C-reactive protein predicts early death in hemodi-Because none of the parameters correlated with Kt/V,
it is likely that underdialysis was not a factor in the alysis patients better than does serum albumin (abstract;
Bergstro¨m et al, J Am Soc Nephrol 6:573, 1995).hypoalbuminemia. The specific cause of inflammation
was not clear to the investigators, who noted the highest Hypoalbuminemia is a powerful predictor of death in
dialysis patients, but the reason is unknown [13]. Anal-C-reactive protein levels in patients with transcutaneous
catheters and arteriovenous grafts. buminemic rats have a normal life span, so hypoalbumi-
nemia per se likely is not the cause [71]. Because protein-Acute phase reactants (APRs) are proteins secreted
by the liver in the presence of stimuli such as infection calorie malnutrition can decrease albumin synthesis, it is
assumed that hypoalbuminemia results mainly from mal-and trauma. These proteins are classified as positive or
negative when synthesis is increased or decreased in in- nourishment in these patients, but albumin synthesis also
can be decreased as part of the acute-phase response [67].flammatory states [69]. The positive APRs are: C-reac-
tive protein, serum amyloid A, a2-macroglobulin, a1-acid Synthesis of APRs is impeded by protein malnutrition
even following an appropriate inflammatory stimulus. Cy-glycoprotein, haptoglobin, ceruloplasmin, ferritin, and
a1-antitrypsin. Negative APRs are albumin, transferrin, tokine release, however, is unimpeded in protein-calorie
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Fig. 3. Two-color flow cytometry detection of
the production of interleukin-6 (IL-6) (x axis)
and IL-10 (y axis) in monocytes of a healthy
control subject and a hemodialysis patient after
stimulation of cells in vitro with lipopolysac-
charide (LPS). Percentages give the portion
of cells above the cutoff for the respective
cytokine or the portion of double-positive
cells. The logarithmic axes of the panels give
the fluorescence intensity (FI) values assigned
to every single cell detected. The MFI is the
mean fluorescence intensity of all cells above
the cutoff. The MFI value is a relative indica-
tor of cytokine production per cell. (Used with
permission from J Am Soc Nephrol [72].)
malnourished states; this suggests that measurements of authors observed a significant increase in IL-1, IL-6, IL-8,
TNF-a, and MCP-1 plasma levels [73, 74]; others foundcytokine levels will provide greater insight into the exist-
ing inflammatory process [71]. no difference or, surprisingly, a reduction [75].
Several studies have addressed the issue of nutritionalNumerous studies have used circulating cytokine lev-
els in patients with ESRD to evaluate the inflammatory parameters and cytokine production. Kaizu et al recently
reported a correlation between pre-dialysis serum IL-6response. However, the physiologic significance of circu-
lating levels remains unclear. These proteins are com- levels and nutritional indices [41]. The authors showed
that patients with high IL-6 levels had lost body weightmonly released locally by leukocytes at the site of in-
flammation and might act primarily by local effects, by more than 4% over three years; serum albumin and
serum creatinine also were lower in the patients with higheither autocrine (acting on the same cell) or paracrine
(acting on a nearby cell). These local cytokine effects IL-6 levels. Evidence also indicates that IL-6 promotes
cancer cachexia [76]. Kehayias and colleagues also corre-would not be detected by changes in circulating levels.
When cytokines react with their cognate receptors, the lated the production of IL-1 receptor antagonist (IL-
1Ra) by PBMCs and nutritional status in 16 hemodialysisreceptors are shed into the serum and are more long
lived, perhaps providing a more accurate measurement patients over a three-month period. They found a direct
correlation of cell content of IL-1Ra with several indicesof cytokine activity [71]. Measurement of cytokine syn-
thesis by peripheral blood mononuclear cells (PBMCs) of nutritional status (body mass index, arm muscle area,
serum cholesterol, and triglycerides) [77].probably offers a more consistent method of assessing
cytokine production in dialysis patients. However, dial-
Relationship between malnutrition, inflammation, andysis patients have profound alterations in the relative
cardiovascular mortalitynumbers of lymphocytes and monocytes in peripheral
blood and with the current standard technique of mea- Discussion has increased regarding the role of dialysis
as a “chronic inflammatory process” contributing to thesurement of cytokines in culture supernatant of mononu-
clear cells (by ELISA), the amount of cytokines is not rapid progression of atherosclerosis in patients with
ESRD. This hypothesis has been further stimulated bygiven in relation to the absolute number of monocytes
[72]. It appears that not even the use of PCR for detection a report on the relation between inflammatory markers
and cardiovascular risk [78]. According to the latestof cytokines has enhanced sensitivity. Girndt et al deter-
mined cytokine production at a single-cell level by flow USRDS Registry report, cardiac causes (cardiac arrest,
acute myocardial infarction, and other cardiac causes)cytometry [72]. Since conventional techniques cannot
differentiate the influence of the relative number of account for almost 50% of the reported causes of dialysis
patient deaths in all age groups (20 to 44, 45 to 64, andmonocytes and lymphocytes in the production of in-
flammatory cytokines, the cytoflow technique gains pre- $65 years). Infection accounts for almost 25% of all
deaths in the 20- to 44-year age group, but only 17%cision because it measures only the products of mono-
cytes (Fig. 3). Compared to ELISA, this method appears and 14% of deaths in the 45- to 64-year and $65-year
age group, respectively [79]. Despite the high prevalenceto have a higher discrimination power (Fig. 4). There
are controversial findings in the literature regarding pro- of malnutrition in chronic dialysis patients, malnutrition
is generally not reported to be a prominent cause ofinflammatory cytokines in hemodialysis patients. Several
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Fig. 4. (A) Cytoflow technique. Detection of
IL-6 at the single-cell level after stimulation
of cells by LPS for 20 hours in vitro. Percent-
age of cells positive for IL-6. Control vs. pa-
tients, P , 0.001. (B) ELISA of IL-6 secretion
in supernatant of peripheral blood leukocytes
(PBL) stimulated with LPS. Control vs. pa-
tients, P , 0.05. (Used with permission from
[72].)
Table 4. Association between mean serum albumin and clinicaldeath, and it is not even listed on the categories for
outcomes (expressed as the effect of a 1.0 g/dL fall) analyzed
causes of death on the ESRD Death Notification Form separately in hemodialysis (N 5 261) and
peritoneal dialysis (N 5 171) patientsa(HCFA-2746) [79]. One can assume therefore that un-
derreporting of death from cachexia is common in the Hemodialysis Peritoneal dialysis
registries and that patients who die from this condition
Relative Relative
are listed under other categories [80]. Outcome risk P risk P
Nevertheless, one needs to explain why hypoalbumi-
Ischemic heart disease
nemia and other nutritional indicators are strong risk De novo 5.29 0.001 NAb NA
Recurrent 4.24 0.005 NA NAfactors for early death, considering that most dialysis
Cardiac failurepatients die of atherosclerotic cardiovascular diseases.
De novo 2.22 0.001 4.16 0.003
The link with infection is easy to understand, because Recurrent 3.84 0.003 NA NA
Mortalitymalnourished, hypoalbuminemic ESRD patients have a
All cause 4.33 ,0.001 2.06 ,0.001high incidence of infection due to defects in cellular
Cardiac 5.60 0.001 NA NA
immunity, neutrophil function, and complement activa- Non-cardiac 3.58 ,0.001 3.52 ,0.001
tion [79]. Additionally, dialysis patients have an elevated aFrom [81].
bNA, not associatedrisk of infection associated with the vascular or perito-
neal access. There is mounting evidence in the recent
literature of an association between inflammatory media-
tors and atherosclerosis and death from myocardial in-
levels of homocysteine that lead to ischemic heart dis-farction and cerebrovascular disease [78]. Accordingly,
ease. Also, evidence suggests increased cytokine genera-one might ascribe the excess cardiovascular mortality
tion in heart failure that is believed to result from tissueseen in dialysis patients with signs of malnutrition to
hypoxia or reduced tissue perfusion and liver congestion.these inflammatory cytokines, which also stimulate pro-
Generated inflammatory cytokines could trigger thetein catabolism and reduce albumin synthesis. Foley et
acute-phase response in the liver and result in decreasedal prospectively studied, for an average of 41 months,
albumin synthesis and thus hypoalbuminemia [80].432 patients with ESRD (261 on hemodialysis and 171
As I mentioned, recent evidence suggests that athero-on peritoneal dialysis). The authors found that among
sclerosis is an inflammatory disease and that the firsthemodialysis patients, a 1.0 g/dL fall in mean serum
step in atherosclerosis is endothelial dysfunction [82].albumin was independently associated with the develop-
Possible causes of endothelial dysfunction leading to ath-ment of de novo and recurrent cardiac failure, de novo
erosclerosis include elevated and modified LDL; freeand recurrent ischemic heart disease, cardiac mortality,
radicals caused by cigarette smoking, hypertension, andand overall mortality (Table 4) [81]. Their analyses
diabetes mellitus; genetic alterations; elevated plasmastrongly suggest that low serum albumin levels came
homocysteine concentrations; infectious micro-organ-before these adverse events and not after. The strong
isms such as Herpesvirus or Chlamydia pneumoniae; andassociation between hypoalbuminemia and ischemic
combinations of these or other factors [82].heart disease led the authors to speculate that low albu-
Hypertriglyceridemia, not an independent risk factormin results in a hypercoagulable state and is associated
for atherogenesis, occurs in 33% to 70% of patients withwith other nutritional deficiencies, such as dietary defi-
ciencies of folic acid, B6, and B12, and increased plasma chronic renal failure; hypercholesterolemia is found in
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as many as 20% of patients. Levels of HDL cholesterol and lower serum levels of these compounds predict hyp-
erhomocysteinemia [89].are decreased in 50% to 75%, and LDL tends to be in
Hypertension has inflammatory actions, increasing thethe normal range [83]. Lipoprotein a [Lp(a)] levels also
formation of hydrogen peroxide and free radicals suchare elevated [83]. Whether Lp(a) is an independent risk
as superoxide anion and hydroxyl radicals in plasma.factor for cardiovascular death in hemodialysis patients
These substances reduce the formation of nitric oxideis currently controversial [84]. In addition to abnormali-
by the endothelium, increase leukocyte adhesion, andties in serum total lipoprotein concentrations, uremic
increase peripheral resistance [82]. Angiotensin II, oftenpatients exhibit potentially atherogenic abnormalities in
elevated in hypertension, is a potent vasoconstrictor andlipoprotein composition, most notably an elevated con-
can contribute to atherogenesis by stimulating the growthcentration of apo C-III [83].
of smooth muscle [82].The apolipoprotein (a) gene promoter region contains
Several reports have correlated the incidence of ath-several hepatocyte-specific, IL-6-responsive elements [85],
erosclerosis with the presence of at least two types ofand this occurrence might explain why Lp(a) levels tran-
infectious microorganisms: Herpesvirus and Chlamydiasiently increase during acute inflammatory states as part
pneumoniae. Both organisms have been identified in ath-of the acute-phase response [86]. High plasma levels of
eromatous lesions, and increased titers of antibodies toLp(a) in hemodialysis patients are closely related to the
these organisms have been detected, but no direct evi-acute-phase reaction, as reflected by elevated levels of
dence has shown that these organisms can cause athero-C-reactive protein, sialic acid, IL-6, serum amyloid A,
sclerotic lesions [82].and fibrinogen [87]. Stenvinkel et al reported that 47%
Several studies have reported the association of acute-of the malnourished uremic patients they studied had a
phase-reactant proteins (indicators of inflammation)higher prevalence of cardiovascular disease and higher
with ischemic heart disease and cerebrovascular disease.C-reactive protein and Lp(a) levels than did those with
Associations were noted between elevated C-reactivenormal nutritional status [88].
protein and the severity of coronary artery atherosclero-Homocysteine is a sulfur-containing amino acid formed
sis [91]; elevated levels of C-reactive protein and serumduring the metabolism of methionine. The rare syn-
amyloid A protein in patients with unstable angina pre-drome of homocystinuria, an autosomal-recessive condi-
dicting more ischemic episodes and higher mortalitytion due to deficiency of cystathionine b-synthase, is
rates [92]; inflammation/infection and increased risk ofassociated with premature atherosclerotic and thrombo-
coronary disease [93]; and elevated C-reactive proteinembolic disease and with excessive quantities of circulat-
levels in the general population and various cardiovascu-ing homocysteine in plasma [89]. Homocysteine is toxic
lar risk factors (increasing age, smoking, increased levels
to the endothelium and is prothrombotic, and it increases
of serum fibrinogen, total cholesterol, triglycerides, and
collagen production and decreases the availability of ni- apolipoprotein B), as well as increased risk of myocardial
tric oxide [82]. Plasma homocysteine concentrations are infarction and stroke [94].
slightly elevated in many patients who have no enzymatic The serum concentration of C-reactive protein reflects
defects in homocysteine metabolism. These patients the activity of cytokine-mediated acute-phase processes
have an increased risk of symptomatic atherosclerosis of [95] and is roughly proportional to the extent of tissue
the coronary, peripheral, and cerebral arteries [82]. High injury [96]. Owen and Lowrie recently reported on the
plasma homocysteine concentrations are seen in chronic serum C-reactive protein levels in 845 hemodialysis pa-
renal failure; deficiencies of folate, vitamin B6, or vitamin tients; 35% of the values in this group exceeded the upper
B12; and other conditions such as malignancies, psoriasis, limit of the laboratory’s reference range. The logistic
and hypothyroidism [89]. High plasma concentrations of regression analysis of the data described a strong, inde-
homocysteine-cysteine mixed disulfide in patients with pendent, inverse relationship between the serum albumin
chronic renal failure and in renal transplant patients were and creatinine concentrations and the odds risk of death,
shown by Wilcken and Wilcken, who first recognized but no such relationship for C-reactive protein [96]. They
altered methionine metabolism as a risk factor for pre- also found that C-reactive protein had an inverse rela-
mature coronary disease [90]. Later, other studies con- tionship with laboratory measures of protein stores (se-
firmed the presence of hyperhomocysteinemia in renal rum albumin, creatinine, and pre-albumin) [96]. Berg-
failure as well as in hemodialysis and CAPD patients stro¨m’s group reported that 53% of 128 hemodialysis
[89]. The causes of hyperhomocysteinemia in renal fail- patients had elevated serum levels of C-reactive protein
ure are unclear, but reduced excretion is not the principal and that over three years of follow-up, it was as strong
cause. The major mechanism is thought to be reduced a predictor of mortality as was hypoalbuminemia (ab-
metabolism, although the exact metabolic derangement stract; Bergstro¨m et al, J Am Soc Nephrol 6:573, 1995).
is unknown [89]. Patients with renal failure are at risk The difference in the two studies might be related to the
number of patients, the use of a more extensive laboratoryfor vitamin deficiencies, particularly folate, B6, and B12,
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the frequency of hospitalizations and mortality rate in
patients on maintenance hemodialysis [100]. Lowrie and
Lew reported the relationship between serum albumin
and mortality rate in 12,000 patients on hemodialysis
[56]. The adjusted risk ratio for mortality increased pro-
gressively as the serum albumin level decreased. For
serum albumin levels of 3.5 to 4.0 g/dL, 3.0 to 3.5 g/dL,
2.5 to 3.0 g/dL, and 2.5 g/dL or less, the adjusted risk
ratios increased exponentially to approximately 2.2, 6.7,
15.3, and 18.5, respectively [56]. Lowrie and Lew also
found that low serum levels of cholesterol, urea, creati-
nine, potassium, and phosphorus also were associated
with an increased risk of mortality. Because these low
values often reflect reduced nutrient intake, these data
likely provide further evidence that decreased nutritional
intake is associated with increased mortality rate. In a
subsequent study of 17,185 patients on hemodialysis,Fig. 5. Kaplan-Meier estimates of survival during follow-up with regard
Lowrie et al concluded that serum albumin was theto cardiovascular mortality in relation to quartiles of serum concentra-
tion of C-reactive protein (CRP). (Used with permission from the strongest single predictor for mortality [101]. The clinical
International Society of Nephrology [98].)
importance of these observations is that approximately
25% of patients on maintenance hemodialysis have low
serum albumin levels (,3.7 g/dL) and serum cholesterol
levels below 155 mg/dL [56], and that these low valuesprofile, and the analysis of outcomes among ambulatory
are within the range associated with increased mortalityESRD patients by Owen and Lowrie instead of hospital-
rates in hemodialysis patients. Similar findings relatingized patients. In a cross-sectional study of 106 CAPD
nutritional status to outcome have been observed inpatients, those with serum albumin ,3.5 g/dL had a serum
chronic peritoneal dialysis patients [102].C-reactive protein significantly greater than those with
This evidence notwithstanding, the association be-serum albumin $ 3.5 g/dL [97]. Kaysen et al also reported
tween nutritional intake or status and clinical outcomethat among hypoalbuminemic patients with ESRD, the
does not indicate a causal relationship [103]. It is possibledegree of hypoalbuminemia correlated with the eleva-
that a co-morbid condition independently impairs bothtion of serum levels of laboratory surrogates of inflam-
nutritional intake or status and increases morbidity andmation, such as C-reactive protein, a2-macroglobulin,
mortality rates. Yet the finding that a low serum albumin,ferritin, and serum amyloid A concentration [67, 68].
independent of Kt/V, the urea reduction ratio, or a co-Zimmermann and colleagues recently examined 280 am-
morbid condition is a risk factor for early death suggestsbulatory patients on maintenance hemodialysis and
that poor nutrition results in increased mortality ratesfound that C-reactive protein and serum amyloid A were
[28]. Moreover, interventions such as intradialytic paren-elevated in almost 50% of the patients in the absence
teral nutrition in malnourished patients on maintenanceof clinically apparent infection, and that those patients
hemodialysis have been shown to reduce mortality rateshad higher serum levels of lipoproteins and fibrinogen
[104].and lower levels of serum albumin, HDL cholesterol,
In short, poor nutrition in dialysis patients—due toand apo A1. After two years, 26% of the patients had
malnourishment or to an inflammatory state—predisposesdied, mostly because of cardiovascular events. As Figure
to increased cardiovascular morbidity and mortality. Re-5 shows, C-reactive protein was a powerful independent
cently, it was shown that urea might contribute to thepredictor of total mortality and cardiovascular death [98].
development of atherosclerotic lesions associated with
Conclusion chronic renal failure and elevated blood urea nitrogen
levels by reducing inducible nitric oxide synthesis withThe evidence that malnutrition is associated with in-
concomitant macrophage proliferation [105]. This phe-creased morbidity and mortality rates in dialysis patients
nomenon could help explain some of the cardiovascularis not new. In 1983, Shapiro et al reported that patients on
events (Fig. 6). In the future, the establishment ofmaintenance hemodialysis with low serum urea nitrogen
“healthy start clinics” might avoid malnutrition at thelevels, an indicator of low dietary protein intake, had
start of dialysis, and the identification of patients withincreased morbidity rates [99]. The same year Acchiardo
high levels of inflammatory mediators might provide anand colleagues reported an inverse correlation between
PCR, also an indicator of dietary protein intake, and opportunity for a more rational intervention.
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Fig. 6. Schematic outline of how uremia
might lead to malnutrition, inflammation, and
cardiovascular mortality.
QUESTIONS AND ANSWERS rives in part from interactions with the inflammatory
system. All this evidence raises the possibility that thera-Dr. Nicolas E. Madias (Chief, Division of Nephrol-
pies targeting chronic low-grade inflammation might pro-ogy, New England Medical Center, Boston, Massachu-
vide novel future strategies for cardiovascular diseasesetts, USA): Thank you very much, Dr. Riella, for your
prevention.wonderful presentation. On the strength of your analysis
Dr. Brian Pereira (Professor of Medicine, New En-of the available data on the relationship among inflam-
gland Medical Center, Tufts University, Boston, Massa-mation, malnutrition, and cardiovascular disease, can
chusetts, USA): I would like to make just two quickyou propose anti-inflammatory strategies aimed at im-
comments. One is in response to Dr. Madias’ questionproving nutritional and cardiovascular outcomes in
about antiinflammatory strategies. In regard to anticy-ESRD?
tokine strategies, the problem is that you are attemptingDr. Riella: I don’t think we are prepared at this
to control the response after it has already occurred. Iftime to propose a single anti-inflammatory strategy. The
you block IL-1, TNF replaces its action, so you need afinding of ongoing inflammation in patients with chronic
number of inhibitors to block inflammatory responses.renal failure prior to the start of dialysis treatment indi-
The ideal is to block the inflammation-inducing stimuluscates that factors independent of hemodialysis treatment
upstream: using ultrapure water for dialysate, more bio-(endotoxins from dialysate, artificial vein grafts, mem-
compatible membranes, and so on. Anticytokine strate-brane bioincompatibility) might play a role in activation
gies have been a complete failure in sepsis, and I thinkof an acute-phase response in uremia.
that controlling inflammatory responses downstream inSome progress has been made in non-renal disorders.
our dialysis patients is likely to be a similar failure.For instance, weight loss in pancreatic cancer is associ-
I would like to make just a small clarification. The factated with persistent activation of the acute-phase re-
is that plasma cytokine levels can be elevated in patientssponse. Oral administration of fish oil (eicosapentaenoic
on hemodialysis or peritoneal dialysis, and in patientsacid, EPA) to patients with pancreatic cancer cachexia
with advanced chronic renal failure who are not on dial-resulted in a significant reduction in the serum concentra-
ysis. But the question we have to answer is, does thistion of the acute-phase reactant C-reactive protein. Pro-
have biologic significance?duction of interleukin-6 by peripheral blood mononu-
Dr. Riella: Numerous studies have used circulatingclear cells from patients receiving EPA was significantly
cytokine levels in ESRD patients to evaluate the role ofreduced [106]. Giving a fish oil-enriched nutritional sup-
inflammatory mediators in the complications associatedplement to pancreatic cancer patients also has attenuated
with dialysis. As you said, the physiologic significance ofprogression of the acute-phase response [107]. In addi-
circulating levels remains unclear. Controversial resultstion, data from randomized clinical trials suggest that
have been reported. While several authors observed athe efficacy of agents such as aspirin [108] and hydroxy-
methyglutaryl (HMG)CoA reductase inhibitors [109] de- significant increase in IL-1, IL-6, TNF-a, IL-8, and
Nephrology Forum: Malnutrition in dialysis 1225
MCP-1 plasma levels, others have found no difference teins [53]. The body then can adapt to a much lower
or, surprisingly, a reduction [110]. This discrepancy in protein intake. The other point was made through the
results likely represents a combination of methodologic data from Bergstro¨m; to maintain nitrogen balance,
differences (earlier studies used bioassays with poor CAPD patients depend more on their caloric intake than
specificity), pulsatile release of cytokines, and other con- on their protein intake [21]. Because we have evidence
current factors that might have affected IL-1 release that many of our patients do take less than the required
(malnutrition, underlying inflammation). Another possi- 35 Kcal/kg/day, you are correct that our emphasis should
ble explanation is that the balance of the cytokine with its be on caloric intake.
circulating inhibitor is more important than the cytokine Dr. Madias: Despite the decreased caloric and nutri-
level per se [69]. ent intake of hemodialysis patients, they have increased
Pertosa et al showed that peripheral blood mononu- energy requirements compared to controls. What might
clear cells of patients undergoing chronic hemodialysis be the explanation for this increased energy require-
presented an activated phenotype as demonstrated by ment?
the striking up-regulation of cytokine gene expression. Dr. Riella: There is no clear explanation. Several
However, the mononuclear cells were unable to synthe- possible mechanisms have been postulated [15]: (1) in-
size and secrete these cytokines [110]. creased myocardial workload, commonly seen in chronic
Dr. Richard Glassock (Professor of Medicine; Head, hemodialysis patients because of interdialytic volume
Department of Medicine; University of Kentucky College expansion, chronic anemia, coronary artery disease, and
of Medicine, Lexington, Kentucky, USA): The thought underlying cardiomyopathy; (2) increased sympathetic
occurred to me, as it perhaps occurred to you, that this nervous system activity, a common finding in the uremic
descriptive analysis of inflammation and atherogenesis state, along with increased levels of cortisol, glucagon,
suggests the ingredients for a vicious Brenner-type cycle. and insulin; (3) increased total-body potassium, which
In other words, atherogenesis begets inflammation, and has been associated with an increase in energy expendi-
inflammation begets atherosclerosis. If true, such a cycle ture.
probably would help explain why inflammation is present Dr. Roberto Garcia (Professor of Medicine and Phar-
before dialysis is initiated. We know that most chroni- macology, Faculty of Medicine, University of Valparaiso,
cally uremic patients already have fairly extensive but Chile): My question relates to the second case that you
sometimes subclinical atherosclerotic disease by the time presented. In my view, this patient illustrates well the
they reach ESRD. Inhibitors of HMG-CoA reductase critical importance of residual renal function. In this
could interrupt this putative vicious cycle of atherogene- patient initially, the total clearance probably was suffi-
sis and inflammation because they not only have potent
cient to maintain her in good condition, but later the
effects on atherogenesis but they also exert anti-inflam-
decline of residual renal function put her into a morematory effects. One might want to examine the possibil-
precarious condition. Moreover, the PET test showed aity of a vicious cycle of atherogenesis and inflammation
high transport pattern. Have you considered switchingbecause of its powerful explanatory role.
this patient to hemodialysis?Dr. Riella: In this same line of reasoning, extremely
Dr. Riella: You are right by saying that the residualrelevant is the recent finding that urea induces macro-
renal function was a contributory factor at the beginning.phage proliferation by inhibition of inducible nitric oxide
If you compare hemodialysis and peritoneal dialysis pa-synthesis [105]. Earlier dialysis might be associated with
tients at the beginning of dialysis, hemodialysis patientslesser atherosclerosis and explain the better survival ob-
have a much higher mortality rate [111]. As time goesserved.
by, the two lines come together; the favorable peritonealDr. Jirgen Ladefoged (Rigshospital, Copenhagen,
dialysis results at the beginning are attributable to resid-Denmark): May I turn to another topic? Would you
ual renal function.please comment on what sort of nutrition we should give
As to transfer to hemodialysis, I would transfer herour uremic patients. I personally think that sufficient
first to an automated therapy, such as nightly intermittentcaloric intake is far more important than protein intake.
peritoneal dialysis (NIPD) or daily ambulatory perito-As far as I can see, there is some tendency in the litera-
neal dialysis (DAPD) because she was a “rapid trans-ture to recommend high protein intakes for our uremic
porter.” Rapid transporters require short dwell times topatients. I think this is wrong because protein is the main
maximize solute clearances and net ultrafiltration. Withsource of fixed acid. In this way we simply increase the
the loss of residual renal function, rapid transportersseverity of metabolic acidosis and thereby produce all
on CAPD can retain fluid, develop hypertension, andthe events you just described.
require more hypertonic exchanges. These patients haveDr. Riella: I agree with you. I’ll try to make this
a tendency to malnutrition and should be transferred toclear by making two comments. One, when you correct
metabolic acidosis, you decrease the oxidation of pro- an automated therapy. I don’t know whether transferring
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such patients to hemodialysis will reduce their increased occur only in those hemodialysis patients whose body
fat exceeds 30%, while others showed no difference frommortality rate.
Dr. Abelardo Aguilera (Peritoneal Dialysis Unit, La controls [38]. Others have shown that in CAPD patients,
serum leptin levels are high and correlate with body massPaz Hospital, Madrid, Spain): I would like to comment
on the results of our recent study [112]. We’ve investi- index, and that peritoneal and urinary losses of leptin
have only a small or negligible effect on serum leptingated the association between plasma TNF-a levels and
the presence of anorexia in peritoneal dialysis patients. concentration [114]. High-flux dialyzers appear to lower
serum leptin levels by 30% [115]. Thus, differences inWe found that anorectic patients had high TNF-a plasma
levels in relation to other peritoneal dialysis patients. serum leptin levels in hemodialysis and CAPD patients
must be interpreted in relation to the body mass fat.TNF-a also showed a negative relationship with venous
pH, serum albumin, pre-albumin, transferrin, cholesterol, Dr. Carlos Hernan Mejia Garcia (Servicio de Tera-
pia Renal Cruz Roja, Cali, Colombia): I have two ques-and other proteins. Our results thus support the hypothe-
sis of a linkage among malnutrition, inflammation, and tions. Is there any role for l-carnitine in dialysis patients?
Second, do we have any evidence for oxidative stress thatanorexia. Did you say that Dr. Bergstro¨m’s group didn’t
find this relation between TNF-a and anorexia? might account for the high prevalence of cardiovascular
disease in malnourished patients?Dr. Riella: No, I didn’t say that. My comment was
related to the possible association between a high-trans- Dr. Riella: About five or six years ago, a Consensus
Conference concluded that routine carnitine supplemen-port peritoneal membrane, as in the case presented, and
inflammatory mediators. Bergstro¨m’s group explored tation in dialysis patients is not justified. Notwithstand-
ing, l-carnitine might be given in the following settingsthis possibility but found no association (Lindholm B,
personal communication). But this does not mean much, when standard therapy has not been effective: intradia-
lytic muscle cramps and hypotension; lack of energy,because a high-transport membrane could result from a
previous inflammatory process. skeletal muscle weakness, and/or myopathy; and cardio-
myopathy and anemia of renal failure unresponsive to orDr. Ce´sar San Martin (Medical Director, RTS Cendyt
Dialysis Unit, Buenos Aires, Argentina): I have two ques- requiring large doses of erythropoietin [116]. Oxidative
stress, which occurs when there is excessive free-radicaltions. Is there any relationship between leptin levels and
cytokines? What do you think of the use of bioimpedance production or low antioxidant levels, has emerged as an
important co-factor for the development of endothelialfor assessing lean and fat mass in patients on dialysis?
Dr. Riella: Cytokines such as TNF-a and IL-1 induce dysfunction and atherogenesis [117]. Free radicals accel-
erate the development of atherosclerosis by generatingboth an increase in leptin mRNA levels and anorexia,
at least in experimental animals [39]. Elevated levels of oxidized LDL, which damages the vascular wall and
causes atherosclerotic lesions. Much recent evidence sug-cytokines have been reported in ESRD patients, so one
might speculate that the inflammatory process itself con- gests that oxidative stress is present in pre-dialysis and
dialysis patients [117]. The causes of increased oxidativetributes to the stimulation of ob gene expression and
thereby increases the circulating leptin levels [39]. stress are not known, but low levels of antioxidants such
as selenium, vitamin C, and gluthathione peroxidaseAlthough bioelectrical impedance analysis (BIA) has
been validated in the estimation of total body water have been implicated.
Dr. Horacio Repetto (Chief, Pediatric Service, Hospi-(TBW), only recently have efforts been made to investi-
gate the role of BIA in nutritional assessment of ESRD tal Nacional, University of Buenos Aires, Argentina): One
of the first symptoms in any child who develops meta-patients. Chertow et al recently showed that BIA is a
valid and reliable method of nutritional assessment in bolic acidosis is decreased appetite. Are you aware of
any study looking at the relationship of acid-base statusmaintenance hemodialysis patients [113]. The group eval-
uated 33 patients on maintenance hemodialysis with BIA, and leptin production?
Dr. Riella: In animal models, both leptin administra-DEXA, and deuterium oxide and sodium bromide iso-
tope dilution studies. It appears that the estimation of body tion and acidosis reduce food intake. In one recent study,
acidotic uremic rats seemed to exhibit lower serum leptincell mass (BCM) is the most valuable aspect of BIA.
Previous studies used fat-free or lean body mass (LBM) levels than did their bicarbonate-supplemented counter-
parts [118].as the focus of body composition analysis, and LBM by
definition includes extracellular water, a body compart- Dr. Vipul Chitalia (Nephrology Fellow, Christchurch
Hospital, Christchurch, New Zealand): Most patientsment typically increased in patients with ESRD [113].
Dr. Madias: Do the levels of leptin differ between with chronic renal failure are faced with continuous in-
flammatory stimuli, and there are spells of superimposedhemodialysis and peritoneal dialysis patients?
Dr. Riella: It seems that serum leptin levels are ele- inflammatory stresses with dialysis. The inflammation in
turn seems to be associated with a rapid decline in resid-vated both in hemodialysis and CAPD patients [39]. Some
investigators have shown that high serum leptin levels ual renal function. My question is: are there studies com-
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paring residual renal function in patients with malnutri- which is obesity. Two months ago, a Jackson group re-
ported that a large percentage of dialysis patients weretion versus those who are not malnourished? This
knowledge might have a great implication on the dose obese. Surprisingly, the authors claim that the one-year
mortality rate was lower in these patients than in theirof dialysis in the future.
Dr. Riella: Several papers have correlated residual non-obese patients [121]. What do you think about this?
Should we be worried about obesity in our dialysis pa-renal function and nutritional status. This relationship was
clearly shown in the CANUSA study [119]. Among 680 tients? Is BMI a good parameter to be used in our dialysis
units?patients on peritoneal dialysis, there was a clinically im-
portant and statistically significant decrease in several esti- Dr. Riella: You’ve brought up a good point. In the
general population, there is evidence that a higher BMImates of nutritional status with decreased renal function.
The estimates of nutritional status were serum albumin is associated with a lower survival rate and more cardio-
vascular complications. I am aware of two papers regard-concentration, SGA, percentage of LBM, and nPCR [119].
Dr. Madias: Does malnutrition affect the ability of ing obesity in dialysis patients, one from the USRDS in
which a BMI below 23.9 was associated with an increasedmonocytes to produce cytokines?
Dr. Riella: A direct correlation exists between nutri- mortality rate. In that same study, a higher BMI in fact
was associated with a lower mortality rate [8].tion and cytokine production, and there is evidence that
malnutrition depresses cytokine production and poten- The second paper is the one you are quoting [121].
The authors measured BMI and biochemical markers oftially contributes to reduced immune responsiveness in
patients on chronic dialysis [120]. nutrition in a large hemodialysis population and found
that 40% were overweight, mainly black females. TheDr. Pereira: This is a response to a query you’ve
raised, Nick. About three years ago, we published data authors found that for every one unit increase in BMI
over 27.5, the relative risk of dying was reduced by 30%.from a study in which we isolated mononuclear cells
from dialysis patients and stimulated those cells with Because this was predominantly an Afro-American
group, and because it is known that within this groupendotoxins. The albumin levels of the patients were di-
rectly correlated with the endotoxin-stimulated IL-1 and females have the highest BMI, this finding simply might
reflect a statistical artifact. But I don’t have a clear an-TNF production. This finding suggested to us that well-
nourished patients’ monocytes seem to be healthier swer for you. At present, I would not suggest obesity as
the cure for malnutrition!based on that one single index [120].
Dr. Tom Parker III (Clinical Professor, University Dr. Madias: Could you please comment on the effi-
cacy of interventions to treat malnutrition in ESRD, suchof Texas, Southwestern Medical School, Dallas, Texas,
USA): It seems as though we are talking about perhaps as administration of rhGH, rhIGF-1, and intradialytic
parenteral nutrition? Under what circumstances, if any,two separate phenomena, or at least a spectrum. We
have patients who are malnourished and in whom there would you recommend these maneuvers?
Dr. Riella: Anabolic hormones such as growth hor-is evidence of inflammation. On the other hand, we have
quite a few patients who are not malnourished by con- mone and its major mediator, insulin-like growth factor
type 1 (IGF-1), have been used in several catabolic states.ventional markers, and yet these patients die of cardio-
vascular disease and have evidence of inflammation. Is The use of growth hormone in uremia is based on a
presumed GH resistance in patients with chronic renalthere a spectrum? Getting to Brian’s point, are there
things we currently are doing under the auspices of mak- failure. Preliminary studies in dialysis patients have sug-
gested that rhGH administration reduces urea genera-ing our patients better but that actually are accelerating
their demise? Should all dialysis patients be on a biocom- tion, improves the efficacy of dietary protein utilization,
and diminishes body protein catabolism. A double-blind,patible membrane? Should everyone be on an endo-
toxin-free dialysate? Should everyone be on high doses placebo-controlled study of rhGH for six months in el-
derly patients undergoing chronic hemodialysis showedof folate? Should the acidosis be corrected in every pa-
tient to decrease the inflammatory response and thereby an increase in serum albumin concentration and in-
creased muscle area and free-fatty mass [122]. However,decrease the cardiovascular disease in patients who do
not have markers of malnutrition? due to the high cost of the therapy, larger and more
prolonged studies will be required to assess the ultimateDr. Riella: You are probably right. Given our current
ignorance in this area, perhaps we should take the avail- effects on quality of life, morbidity, and mortality.
Recombinant human growth hormone also promotesable evidence and implement many of the actions you
are suggesting. growth in children with chronic renal failure; it is ap-
proved by the US Food and Drug Administration (FDA)Dr. Mahmoud M. Salem (Assistant Professor of Medi-
cine, Division of Nephrology, The University of Missis- for this purpose, and changes in body composition can
be expected during growth hormone treatment [123].sippi Medical Center, Jackson, Mississippi, USA): I want
to change the subject to another aspect of malnutrition, The agent responsible for the most of the anabolic effects
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of growth hormone, IGF-1 is not approved by the FDA postulate a dichotomous differentiation of monocytes in
analogy to that seen in T-lymphocytes (Th1 and Th2).for use as an anabolic agent. Due to the twice-daily
dosing schedule and toxic effects (jaw pain, nausea, hy- Possibly monocytes also differentiate into populations
with different functions [72].poglycemia, occasional altered mentation, cardiac ar-
rhythmias), it is less desirable than growth hormone. Dr. Madias: Regarding your point on correcting the
metabolic acidosis of hemodialysis patients by raising theIntradialytic hormone nutrition (IDPN) is provided
during the hemodialysis procedure, and because it is bicarbonate concentration of the dialysate, experience
suggests that this is not an easily accomplished task [57].given only for four hours thrice weekly, it is a method of
nutritional supplementation rather than total nutritional This difficulty is analogous to the fact that introduction
of high-flux dialysis, increases in dialysis time, and highersupport. The potential benefits and indications for IDPN
have not been investigated adequately in large-scale, blood flow rates have not produced a higher pre-dialysis
plasma bicarbonate concentration [126]. The most rea-randomized, prospective clinical trials. Such trials should
include comparisons between IDPN and other methods sonable explanation for the major discrepancy between
the amount of bicarbonate delivered to the patient dur-of nutritional management, such as dietary counseling,
food supplements, and enteral tube feeding, to deter- ing hemodialysis and the attained plasma bicarbonate
concentration is marked stimulation of organic acid pro-mine the relative benefits and risks and the therapeutic
indications for each of these treatment modalities. Sev- duction by the rapid alkalinization of body fluids. The
resultant outpouring of protons titrates bicarbonate ions,eral studies have suggested a limited benefit of IDPN
on nutritional parameters in non-uniform samples of pa- whereas the loss of the organic anions in the dialysate
prevents bicarbonate regeneration. Thus, rather than in-tients. Chertow et al, in a retrospective cohort study,
showed a survival advantage among hypoalbuminemic creasing plasma bicarbonate concentration substantially,
raising the bicarbonate concentration of the bath appearsIDPN recipients [104]. Given its expense and the absence
of more definitive data, its use probably should be limited to induce a catabolic process. I believe that the acid-base
and metabolic responses to increasing the bicarbonateto patients who are unable to tolerate oral or enteral
nutrients or formulas designed to meet protein-energy concentration in the dialysate require careful study be-
fore we recommend that increase as a measure of correct-requirements. Except for the patient with a permanently
and totally diseased gastrointestinal tract, IDPN should ing metabolic acidosis. A more effective means for this
purpose might be oral bicarbonate supplementation.be a short-term resuscitative therapy [124].
Dr. Paul Kimmel (Division of Renal Disease and Hy- Dr. Riella: If I may add, high-concentration bicar-
bonate dialysis (36 mmol/L) has been associated withpertension, Department of Medicine, George Washington
University Medical Center, Washington, DC, USA): Again, hypoxemia during dialysis. A lower concentration of bi-
carbonate in dialysate prevented hypoxemia [127].I would like to compliment you on your approach to this
difficult topic. To illustrate how difficult it is, there are Dr. Madias: As you know, Dr. Mitch’s work has
shown that glucocorticoids are necessary to mediate theoutcome data on circulating cytokines and survival on
dialysis patients. We recently reported data showing that catabolic effects of NH4Cl-induced metabolic acidosis,
such as increased protein degradation and amino acidcirculating levels of IL-1 and other inflammatory cyto-
kines predict death [125]. But the more interesting find- oxidation. Is it known whether glucocorticoids also are
necessary to mediate the catabolic effects of uremic aci-ing was that IL-2 and IL-12 (cytokines critical for T-cell
growth and function), IL-4, IL-5, T-cell number and func- dosis in animals or humans?
Dr. Riella: The studies by Mitch were done in thetional status, and CH50 were independently associated
with survival. The levels of particular cytokines, while intact rat, but Garibotto et al found that the rate of
protein degradation measured in the forearm of patientspredictive of mortality, might not be causally linked to
effectors of outcome. For example, IL-1, a mortality with chronic renal failure was inversely related to the
serum bicarbonate concentration but linearly related tofactor in our study, increases synthesis of IL-2 (a corre-
late of survival) by lymphocytes, suggesting that its asso- the plasma cortisol concentration [128].
Dr. John Donohoe (Consultant Nephrologist, Beau-ciation with mortality must be mediated through other
pathways. The cytokine network is so difficult to manipu- mont Hospital, Dublin, Ireland): It seems to me that the
total quantity of clearance appears to be a dominantlate, and it is so interrelated, that it probably makes
intervention very difficult. feature. Patients can tolerate very low levels of renal
function before finally becoming uremic and needingDr. Riella: Thank you. To further illustrate the com-
plexity of the cytokine network, one is reminded that in dialysis. I wonder whether what we are doing at the
moment is attempting to make the best of a poor substi-healthy people, monocytes differentiate into populations
that mutually exclusively express IL-6 (an inflammatory tute for renal function. For example, when patients who
are extremely ill receive a renal transplant, their malnu-cytokine) or IL-10 (a regulator of monocyte activation
that downregulates inflammatory cytokines). One might trition disappears immediately and often is replaced by
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Gaskin KJ, Truswell AS: Body protein of patients undergoingobesity just a few months later. So I wonder, on a quan-
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tum basis, where would you place the role of clearance 3. Guarnieri G, Toigl G, Situlin R, Faccini L, Coli U, Lannini
S, Bazzato G, Dardi F, Campanacci L: Muscle biopsy studiesamong the inflammatory problems, metabolic acidosis,
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